HER2/neu (ERBB2) Gene Amplification, FISH, Urothelial Carcinoma
The HER-2/neu (human epidermal growth factor receptor 2) is a transmembrane protein with tyrosine kinase activity with a wide range of function such as cell signaling, cell growth and differentiation. It is a proto-oncogene whose gene amplification can lead to tumor development through enhanced cell proliferation, survival, motility, and adhesion. The specific ligand for HER-2/neu is currently not known. HER-2/neu protein overexpression has been show to correlate with an adverse prognosis, particularly in breast and ovarian cancer. HER-2/neu amplification and overexpression are observed in approximately 20% of invasive breast cancers and are associated with an aggressive disease course and decreased disease-free and overall survival. HER-2 status is most often used to determine patient eligibility for trastuzumab immunotherapy. The drug consists of humanized monoclonal antibody blocking the extracellular domain of HER-2, which then inhibits proliferation of human tumors cells that overexpress the receptor.
Breast tumors with the amplified HER-2 gene and/or that overexpress the HER-2 protein are suitable for treatment with trastuzumab or other immunotherapy that might have similar inhibitory function. HER-2/neu overexpression is also a predictor of response to certain breast cancer therapies, including targeted immunotherapies. HER-2/neu protein is usually not detectable in normal human tissue.
Currently the most common means of evaluating HER-2 protein overexpression is by immunohistochemistry of tumor cells in formalin fixed paraffin embedded tissue specimens. The methodology has been standardized with a cutoff of percentage of positive cells and strength of positivity above which the test is considered positive. In equivocal cases by immunohistochemistry, the specimen is reflexed for FISH testing for HER-2/neu gene amplification using the same paraffin embedded tissue. In this method, tumor cells are stained with two fluorescent dyes linked to sequence specific probes, one against (sequence specific) the HER-2/neu gene and another against chromosome 17. A ratio of HER-2 to chromosome 17 signals is calculated using direct observation by a fluorescence microscope and a ratio of 2 or greater is generally considered positive. Testing for HER-2 overexpression, either by immunohistochemistry (IHC) or by fluorescence in situ hybridization (FISH) is therefore recommended before prescribing trastuzumab and/or other inhibitory therapy.
- To predict 5-year disease-free and overall survival in patients with breast cancer
- To assess eligibility for trastuzumab (Herceptin®) treatment
- To assist in dose selection for certain drugs
- To predict response to drug therapies
- Disease management
Immunohistochemistry (HercepTest):
- 0 and 1+: Negative
- 2+: Equivocal
- 3 and 4+: Positive
FISH:
- Negative: Less than 2.0:1.0 ratio of HER-2 signals to chromosome 17 signals
- Positive: 2.0:1.0 or greater ratio of HER-2 signals to chromosome 17 signals OR an average of 6 or more copies of the HER2 gene per tumor cell.
HER-2/neu amplification and overexpression are observed in approximately 20% of invasive breast cancers.
HER-2/neu amplification and overexpression are associated with an aggressive disease course.
HER-2/neu amplification and overexpression decreases disease-free and overall survival.
Might be overexpressed in ovarian and some other cancers.
HER-2/neu protein overexpression is detected using the HercepTest immunohistochemistry technique by the examination of stained slides by light microscopy. A standardized scoring system has been developed in which tumors showing 0 and 1+ expression are considered negative, those showing 2+ expression are considered equivocal and those showing 3 and 4+ over expression are considered positive. Tumors with 2+ score by HercepTest are reflexed to HER-2/neu gene analysis by FISH and the ratio of HER-2 genes to chromosome 17 genes is calculated.
Immunohistochemistry and FISH utilize formalin fixed paraffin embedded tissue.
Western blot and Southern blot require fresh or frozen tissue.
1-5 days.
- J Clin Oncol. 2007; 25(1):118-45 (Epub 2006 Dec 11). [PMID: 17159189]
- Am J Clin Pathol. 2000; 113(6): 852-9. [PMID: 10874886]
- Ann Clin Lab Sci. 1998; 28(4): 215-23. [PMID: 9715348]
- J Cell Physiol. 2000; 182(2): 150-62. [PMID: 10623878]
- Am J Pathol. 2001; 115(4): 504-11. [PMID: 11293897]
- Breast Cancer Res Treat. 1998; 52(1): 77. [PMID: 10066073]
- Cancer Res. 1993; 53(20):4960-70. [PMID: 8104689]
- J Clin Oncol. 1990; 8(1):103-12. [PMID: 1967301]
- J Clin Oncol. 1989; 7(8):1120-8. [PMID: 2569032]
- Arch Pathol Lab Med. 2000; 124(7):966-78. [PMID: 10888772]